Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2021-01-27 Regulatory Filings
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with Regulation 39(3) of the SEBI Listing Obligations and Disclosure Requirements, 2015. It informs about the issuance of a duplicate share certificate due to loss/misplacement of the original certificate. The content is a regulatory announcement related to share certificates and does not contain financial data, management discussion, or report content. It is not a full report, earnings release, or management information. The document is a regulatory compliance announcement related to shareholding records and is best classified under Regulatory Filings (RNS) as it does not fit other specific categories.
2021-01-27 English
Pursuance to Regulation 39(3) of the SEBI Listing Regulations we wish to inform you that the Company has issued a Duplicate Share Certificate on January 25, 2021 in lieu of the original ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the issuance of a duplicate share certificate due to loss/misplacement of the original certificate. The content is a regulatory announcement related to share certificate issuance and does not contain financial data, management discussion, or report details. It is not a financial report, earnings release, or management report. It is a regulatory filing informing the exchanges and public about a corporate action related to share certificates. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is short and it is a formal compliance communication, fitting the RNS category with high confidence.
2021-01-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product by Unichem Laboratories Limited. It is addressed to stock exchanges under SEBI regulations and contains no financial statements, management discussion, or detailed financial data. The document length is 3616 characters, which is relatively short and primarily serves as a regulatory announcement of a significant event (product approval). It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is the announcement itself, not about a report. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-01-27 English
Announcement Under Regulation 30 (LODR) - ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product by Unichem Laboratories Limited. It is addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a regulatory announcement about a significant corporate event (product approval) rather than a financial report or earnings release. The document length is 3616 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-01-27 English
Copy of Newspaper Publication
Regulatory Filings
2021-01-25 English
Board meeting Intimation published in newspaper on January 23, 2021
Regulatory Filings
2021-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.